Target intelligence / Profile preview

Norepinephrine Signaling in Vascular Smooth Muscle Cells (NE Signaling in VSMCs)

Target
NE Signaling in VSMCs
Molecular classification
Neurotransmitter Signaling, G protein-coupled receptor signaling, Enzyme-mediated metabolism, Eicosanoid signaling
01

Overview

Norepinephrine (NE) signaling in vascular smooth muscle cells (VSMCs) is a complex process involving adrenergic receptor activation, intracellular signaling cascades, and metabolic pathways. NE primarily mediates vasoconstriction and influences cellular metabolism, promoting VSMC proliferation, migration, and phenotypic switching. Dysregulation of NE signaling contributes to the pathogenesis of hypertension, atherosclerosis, and other vascular diseases. Therapeutic interventions targeting this pathway aim to modulate adrenergic receptor activation, arachidonic acid metabolism, and extracellular vesicle-mediated communication to restore normal vascular function.

Other names
Noradrenaline Signaling in Vascular Smooth Muscle CellsNE Metabolism in VSMCsNorepinephrine effects on VSMC function
02

Mechanism of action

Varies depending on the specific target (e.g., receptor antagonism, enzyme inhibition). General mechanisms involve modulating adrenergic receptor activation, inhibiting arachidonic acid metabolism, or interfering with extracellular vesicle signaling.

03

Biological functions

Regulation of vascular toneVasoconstrictionCell proliferationCell migrationPhenotypic modulation of smooth muscle cellsSignal transductionExtracellular vesicle-mediated communication
04

Disease associations

HypertensionAtherosclerosisVascular remodelingPulmonary hypertensionSystemic hypertension
05

Safety considerations

Non-selective adrenergic receptor blockade can lead to hypotension or bronchoconstriction.Inhibition of eicosanoid synthesis can have diverse effects on inflammation and thrombosis.Long-term modulation of sympathetic activity can have complex cardiovascular consequences.
06

Interacting drugs

Alpha-adrenergic receptor antagonists (e.g., Prazosin)

5 more in the full profile.

07

Biomarkers

Plasma norepinephrine levelsUrinary catecholamine levelsLevels of 20-HETE and other eicosanoidsExpression of adrenergic receptors in VSMCsMarkers of VSMC proliferation (e.g., PCNA, Ki-67)

Beyond the preview

Go deeper on Norepinephrine Signaling in Vascular Smooth Muscle Cells (NE Signaling in VSMCs).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Norepinephrine Signaling in Vascular Smooth Muscle Cells (NE Signaling in VSMCs).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call